Nodal Marginal Zone B-Cell Lymphoma is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Nodal Marginal Zone B-Cell Lymphoma have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Nodal Marginal Zone B-Cell Lymphoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nodal Marginal Zone B-Cell Lymphoma overview

Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL may be associated with Sjogren syndrome, an autoimmune disorder that affects the salivary and tear glands. NMZL can cause symptoms such as painless swelling of the lymph nodes, fever, night sweats, weight loss, and skin rash. The diagnosis of NMZL is based on a biopsy of the affected lymph node and other tests to determine the stage and subtype of the disease. The treatment of NMZL depends on the stage, symptoms, and general health of the patient. It may include chemotherapy, radiation therapy, surgery, or targeted therapy with monoclonal antibodies.

For a complete picture of PTSR and LoA scores for drugs in Nodal Marginal Zone B-Cell Lymphoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.